

| Patient Name: | |
|---------------|--|
| DOB: | |

LECANEMAB-IRMB (LEQEMBI™) INFUSION ORDERS

| | ELO/III | EIVINID IIVIND (EE) | Z = 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | JOION OND | |
|----|--|--|---|---|--|
| 1) | Diagnosis: □ G30.0 Alzheimer's Disease, Ea □ G30.1 Alzheimer's Disease, La □ G30.8 Other Alzheimer's disease □ G30.9 Alzheimer's disease, und □ G31.84 Mild Cognitive Impairm | te Onset se | es require | disturbance F02.81 Dementi disturbance | ia without behavioral ia with behavioral Description) |
| | Gender: DM DF | Height: | □ CM □ IN | Weight: | □ KG □ LB |
| 3 | □ Beta Amyloid Pathology Confirme □ Amyloid PET Scan Date: □ Cognitive Assessment Used: □ ApoE ε4 Genetic Test Date: Pre-Infusion: □ Confirm base □ Confirm MRI □ Measure and □ Hold infusion □ Headac □ Dizzines □ Nausea □ Vision completes □ Nausea □ Vision completes | Result: line MRI results prior to initiation completed and reviewed by provider deach tree and notify provider if patient researches. | CSF Analysis [Homozygote con of treatment. escriber prior to the 5th catment to determine do | Date: Date: Heterozygote 1, 7th, and 14th trea | ide documentation): _ Result: Result: _ Noncarrier |
| | Medication: | ✓ Administer LEQEMBI | 10 mg/kg intraver | nously over at le | east 60 minutes. |
| | ✓ Dilute required volume of lection binding 0.2-micron in-line filter ✓ If infusion-related reaction occurrence | er. | | | |
| | Treatment Frequency | cars, stop infusion and ti | eat per orders, pro | tocor as chinical | ry maicated. |
| | Schedule treatments ever Post-Infusion: Educate patient/care par Fax treatment notes to p | rtner to report headache, | , dizziness, nausea, | vision changes, | or new/worsening confusion |
| | Prescriber name (print): | | | | |
| | Prescriber signature: | | | | ninin |
| | Date: | | | — | . O G O G O |

